Skip Nav Destination
Issues
1 October 2012
-
Cover Image
Cover Image
Harbinski and colleagues performed a high-throughput screen of the human secretome to identify proteins capable of rescuing growth of receptor tyrosine kinase (RTK)–addicted cells following RTK inhibition and observed numerous potential ligand-mediated resistance mechanisms. Multiple human epidermal growth factor (HER) and fibroblast growth factor (FGF) ligands could rescue growth of hepatocyte growth factor (HGF) receptor (MET)–addicted cancer cells following MET inhibition, and FGFR-addicted cell lines treated with FGFR inhibitors could be rescued by HER ligands or HGF. Combination therapy modalities targeting the broad compensatory relationship between MET, FGFR, and HER ligands may thus have improved clinical efficacy. For details, please see the article by Harbinski and colleagues on page 948. - PDF Icon PDF LinkTable of Contents
ISSN 2159-8274
EISSN 2159-8290
Issue Sections
In This Issue
In the Spotlight
In Focus
Review
Research Briefs
Comparative Genomic Analysis of Esophageal Adenocarcinoma and Squamous Cell Carcinoma
Nishant Agrawal; Yuchen Jiao; Chetan Bettegowda; Susan M. Hutfless; Yuxuan Wang; Stefan David; Yulan Cheng; William S. Twaddell; Nyan L. Latt; Eun J. Shin; Li-Dong Wang; Liang Wang; Wancai Yang; Victor E. Velculescu; Bert Vogelstein; Nickolas Papadopoulos; Kenneth W. Kinzler; Stephen J. Meltzer
Research Articles
VEGF/Neuropilin-2 Regulation of Bmi-1 and Consequent Repression of IGF-IR Define a Novel Mechanism of Aggressive Prostate Cancer
Hira Lal Goel; Cheng Chang; Bryan Pursell; Irwin Leav; Stephen Lyle; Hualin Simon Xi; Chung-Cheng Hsieh; Helty Adisetiyo; Pradip Roy-Burman; Ilsa M. Coleman; Peter S. Nelson; Robert L. Vessella; Roger J. Davis; Stephen R. Plymate; Arthur M. Mercurio
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation
Ken Takezawa; Valentina Pirazzoli; Maria E. Arcila; Caroline A. Nebhan; Xiaoling Song; Elisa de Stanchina; Kadoaki Ohashi; Yelena Y. Janjigian; Paula J. Spitzler; Mary Ann Melnick; Greg J. Riely; Mark G. Kris; Vincent A. Miller; Marc Ladanyi; Katerina Politi; William Pao
Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
Dalia Ercan; Chunxiao Xu; Masahiko Yanagita; Calixte S. Monast; Christine A. Pratilas; Joan Montero; Mohit Butaney; Takeshi Shimamura; Lynette Sholl; Elena V. Ivanova; Madhavi Tadi; Andrew Rogers; Claire Repellin; Marzia Capelletti; Ophélia Maertens; Eva M. Goetz; Anthony Letai; Levi A. Garraway; Matthew J. Lazzara; Neal Rosen; Nathanael S. Gray; Kwok-Kin Wong; Pasi A. Jänne
Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth
Fred Harbinski; Vanessa J. Craig; Sneha Sanghavi; Douglas Jeffery; Lijuan Liu; Kelly Ann Sheppard; Sabrina Wagner; Christelle Stamm; Andreas Buness; Christian Chatenay-Rivauday; Yao Yao; Feng He; Chris X. Lu; Vito Guagnano; Thomas Metz; Peter M. Finan; Francesco Hofmann; William R. Sellers; Jeffrey A. Porter; Vic E. Myer; Diana Graus-Porta; Christopher J. Wilson; Alan Buckler; Ralph Tiedt
News in Brief
News in Depth
Research Watch
Chemotherapy
Clinical Trials
Colorectal Cancer
DNA Repair
Drug Discovery
Drug Resistance
Drug Response
Glioblastoma
Immune Evasion
Immunotherapy
Leukemia
Lung Cancer
Metabolism
Metastasis
Microbiome
Mutations
Neuroblastoma
Signaling
Stem Cells
Targeted Therapy
Transcription
Tumor Suppressors
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.